Teva Entitled To Exclusivity Period For Generic Pravachol – D.C. Court
This article was originally published in The Tan Sheet
Executive Summary
Teva's 180-day marketing exclusivity period for its generic equivalent of Bristol-Myers Squibb's Rx Pravachol (pravastatin) has "neither expired nor even commenced," District of Columbia District Court ruled Oct. 21